BioHaven
Biohaven begins a clinical trial will assess the potential benefits of CGRP receptor-blockade in mitigating an excessive immune response which in some cases can be fatal in COVID-19
Rankings by
National Ranking282nd
in United States Regional Ranking316th
in North America and Caribbean Global Ranking773rd
worldwide